lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Secondary Prevention of Antithrombotic Therapy in Patients with Stable Cardiovascular Disease at High Ischemic Risk: A Network Meta-Analysis of Randomized Controlled Trials

32 Pages Posted: 16 Jun 2021

See all articles by Houyong Zhu

Houyong Zhu

Hangzhou Hospital of Traditional Chinese Medicine

Xiaoqun Xu

Hangzhou Red Cross Hospital

Xiaojiang Fang

Hangzhou Hospital of Traditional Chinese Medicine

Liuguang Song

Hangzhou Hospital of Traditional Chinese Medicine

Jianwu Zheng

Hangzhou Hospital of Traditional Chinese Medicine

Beibei Gao

affiliation not provided to SSRN

Guoxin Tong

affiliation not provided to SSRN

Liang Zhou

Zhejiang University - Department of Cardiology

Tielong Chen

Zhejiang Chinese Medical University - Department of Cardiology,

Jinyu Huang

Zhejiang University - Department of Cardiology

More...

Abstract

Backgroud: Antithrombotic secondary prevention in stable cardiovascular disease (SCVD) patients at high ischemic risk remains unclear. We compared aspirin monotherapy; ticagrelor monotherapy; clopidogrel monotherapy; rivaroxaban monotherapy; rivaroxaban plus aspirin; ticagrelor plus aspirin; and clopidogrel plus aspirin in cohorts at high ischemic risk such as coronary artery disease (CAD) with multi-vessel disease or history of miocardial infarction (MI), symptomatic peripheral artery disease (PAD) or limb revascularization or amputation, or asymptomatic carotid stenosis.

Methods: Eleven randomized controlled trials were included. The primary outcomes were major cardiovascular and cerebrovascular events (MACEs) and major bleeding, which constituted net clinical benefit. A random effects model was used for frequency network meta-analysis. Odds ratio (OR) and 95% credible intervals (CI) were reported as a summary statistic.

Results: Among 111737 patients, the median follow-up was 24 months. Compared with aspirin monotherapy, rivaroxaban plus aspirin [OR 0.79 (95% CI, 0.69, 0.89)], ticagrelor plus aspirin [0.88 (0.80, 0.98)], clopidogrel plus aspirin [0.56 (0.41, 0.77)] were associated with a reduced risk of MACEs, but rivaroxaban monotherapy [0.92 (0.79, 1.07)], ticagrelor monotherapy [0.68 (0.45, 1.05)], and clopidogrel monotherapy [0.67 (0.43,1.05)] showed no statistically significant difference. However, rivaroxaban monotherapy regimens and all dual antithrombotic strategies increased the risk of major bleeding to varying degrees, with ticagrelor plus aspirin associated with the highest risk of major bleeding. The net clinical benefit favored clopidogrel monotherapy or ticagrelor monotherapy, which have a mild anti-ischemic effect without an increase in bleeding risk. Rivaroxaban plus aspirin favored a reduction in all-cause or cardiovascular death or ischemic stroke, and P2Y12 inhibitors favored a reduced risk of MI. The results for the efficacy and safety outcomes in the CAD and PAD subgroups were similar to the results for the whole cohort.

Conclusions: The present network meta-analysis suggests that clopidogrel or ticagrelor monotherapy may be recommended first in this cohort of SCVD at high ischemic risk. But clopidogrel plus aspirin or rivaroxaban plus aspirin can still be considered for use in patients with recurrent MACEs.

Funding: This study was supported by the Science Technology Department of Zhejiang Province (2019C03SA100640), the Zhejiang Health Commission (2021KY916), and the Hangzhou Science and Technology Bureau (A20200624 and 20201203B178). The sponsors played no role in the study design, data collection and analysis, or decision to submit the article for publication.

Declaration of Interest: None to declare.

Keywords: stable cardiovascular disease; secondary prevention; antithrombotic therapy

Suggested Citation

Zhu, Houyong and Xu, Xiaoqun and Fang, Xiaojiang and Song, Liuguang and Zheng, Jianwu and Gao, Beibei and Tong, Guoxin and Zhou, Liang and Chen, Tielong and Huang, Jinyu, Secondary Prevention of Antithrombotic Therapy in Patients with Stable Cardiovascular Disease at High Ischemic Risk: A Network Meta-Analysis of Randomized Controlled Trials. Available at SSRN: https://ssrn.com/abstract=3868068 or http://dx.doi.org/10.2139/ssrn.3868068

Houyong Zhu

Hangzhou Hospital of Traditional Chinese Medicine ( email )

China

Xiaoqun Xu

Hangzhou Red Cross Hospital ( email )

Hangzho
China

Xiaojiang Fang

Hangzhou Hospital of Traditional Chinese Medicine ( email )

China

Liuguang Song

Hangzhou Hospital of Traditional Chinese Medicine ( email )

China

Jianwu Zheng

Hangzhou Hospital of Traditional Chinese Medicine ( email )

China

Beibei Gao

affiliation not provided to SSRN

No Address Available

Guoxin Tong

affiliation not provided to SSRN

No Address Available

Liang Zhou

Zhejiang University - Department of Cardiology

Hangzhou
China

Tielong Chen

Zhejiang Chinese Medical University - Department of Cardiology,

Hangzhou, Zhejiang
China

Jinyu Huang (Contact Author)

Zhejiang University - Department of Cardiology ( email )

Hangzhou
China